

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|--|---|
| (51) International Patent Classification ⁶ : C07C 291/00 | | A2 | (11) International Publication Number: WO 99/01427 (43) International Publication Date: 14 January 1999 (14.01.99) |
| (21) International Application Number: PCT/US98/13723 | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). | |
| (22) International Filing Date: 1 July 1998 (01.07.98) | | Published <i>Without international search report and to be republished upon receipt of that report.</i> | |
| (30) Priority Data: 60/051,690 3 July 1997 (03.07.97) US | | | |
| (71) Applicant (<i>for all designated States except US</i>): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health Office of Technology Transfer [US/US]; Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US). | | | |
| (72) Inventors; and | | | |
| (75) Inventors/Applicants (<i>for US only</i>): HRABIE, Joseph, A. [US/US]; 630 Grant Place, Frederick, MD 21702-4144 (US). KEEFER, Larry, K. [US/US]; 7016 River Road, Bethesda, MD 29817 (US). | | | |
| (74) Agents: GAGALA, Bruce, M. et al.; Leydig, Voit & Mayer, Ltd., Two Prudential Plaza, Suite 4900, 180 North Stetson, Chicago, IL 60601-6780 (US). | | | |
| (54) Title: NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME | | | |
| (57) Abstract | | | |
| <p>The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions comprising such compounds, methods of using such compounds and compositions, and to a method for the preparation of nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakhstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME

5

FIELD OF THE INVENTION

The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, to compositions comprising such compounds, to methods of using such compounds and compositions, to a method for 10 the preparation of nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.


15

BACKGROUND OF THE INVENTION

Nitric oxide (NO) has been implicated as part of a cascade of interacting agents involved in a wide variety of bioregulatory processes, including the physiological control of blood pressure, macrophage-induced cytostasis 20 and cytotoxicity, and neurotransmission (Moncada et al., "Nitric Oxide from L-Arginine: A Bioregulatory System," Excerpta Medica, International Congress Series 897, Elsevier Science Publishers B.V.: Amsterdam (1990); Marletta et al., Biofactors 2: 219-225 (1990); Ignarro, 25 Hypertension (Dallas) 16: 477-483 (1990); Kerwin et al., J. Med. Chem. 38: 4343-4362 (1995); and Anggard, Lancet 343: 1199-1206 (1994)). Given that NO plays a role in such a wide variety of bioregulatory processes, great effort has been expended to develop compounds capable of 30 releasing NO. Some of these compounds are capable of releasing NO spontaneously, e.g., by hydrolysis in aqueous media, whereas others are capable of releasing NO upon being metabolized (Lefer et al., Drugs Future 19: 665-672 (1994)).


35 Keefer et al. (U.S. Patent Nos. 4,954,526; 5,039,705; 5,155,137; 5,208,233 and 5,405,919 and related patents and patent applications, all of which are incorporated herein by reference) disclose, among others,

the use of certain nucleophile/nitric oxide adducts as NO-releasing agents, i.e.,




in which the nucleophilic residue (Nuc) is a primary
 5 amine, a secondary amine or a polyamine. Although such adducts offer many advantages over other currently available nitric oxide-releasing compounds, one
 10 disadvantage presented by the use of such adducts as pharmaceutical agents is the potential risk of release of nitrosamines, which are carcinogenic, upon decomposition and release of NO. Another disadvantage of the adducts of primary amines is that they can be unstable even as solids due to a tendency to form traces of potentially explosive diazotates.

15 Several types of compounds of the general structure



have been known for many years. Traube (Liebigs Ann. Chem. 300: 81-123 (1898)) reported the preparation of a number of such compounds and noted that treatment of the
 20 compounds with acid produced a "brown gas." Although brown gas suggests the release of NO, given that a brown gas also may be produced in the disproportionation of nitrite, the release of brown gas by the compounds prepared by Traube is not, in and of itself, evidence of
 25 NO release. Compounds of the structural type reported by Traube are known to require harsh treatment with mineral acids to release any gas which is, of course, incompatible with a biological utility.

Another compound, which has the structure



- 5 and which has been named cupferron, has been shown by Kubrina et al., Izvestia Akademii Nauk SSSR Seria Biologicheskaiia 6: 844-850 (1988)) to generate NO *in vivo*. In addition, the antibiotics alanosine (C(O)(OH)CH(NH₂)CH₂N(O)=NOH) and dopastin 10 (CH₃CH=CHC(O)NHCH₂CH(i-propyl)-N(O)=NOH), as well as cupferron, have been shown to release NO *in vivo* by enzymatic oxidation (Alston et al., J. Biol. Chem. 260: 4069-4074 (1985)).

More recently, Keefer et al., in U.S. Patent No. 15 5,212,204, have broadly described that an organic moiety may be linked via carbon to the N₂O₂⁻ group. This patent does not disclose an amidine or enamine structure as the nucleophile, nor does it teach the nature of the structural characteristics that an organic moiety must possess to cause the resulting N₂O₂⁻ group to be a nitric oxide donor.

Some N₂O₂⁻-containing compounds have been disclosed to be useful as curing agents in rubber manufacture, antiknock additives for gasoline, indicator dyes, 25 explosives, corrosion inhibitors and fungicides (Danzig et al., U.S. Patent No. 3,309,373; Wiersdorff et al., Chem Abstracts 77: 48034f (1972); Massengale, U.S. Patent No. 2,635,978; and Metzger et al., U.S. Patent No. 2,954,314). However, the mechanism of the reported 30 action of these compounds was not described.

In this regard, a recent study of the N₂O₂⁻ group (Taylor et al., J. Org. Chem. 60: 435-444 (1995)) proposed a mechanism for the observed NO release. The proposed mechanism was based on quantum mechanical 35 calculations which showed protonation at the terminal

oxygen to be most favored thermodynamically in the case of N bound N_2O_2^- .

None of the above disclosures, however, mention anything about the release of nitroxyl (HNO, which, at 5 the physiological pH of 7.4, exists as NO^-) by this functional group. Recent results suggest that, under certain conditions, many classes of "NO donors" may release some NO^- (see the discussions for nitrosothiols and diazeniumdiolates as well as the table of NO donors 10 in Feelisch et al., *Donors of Nitrogen Oxides*, In Methods in Nitric Oxide Research, M. Feelisch and J.S. Stamler, Eds., Ch. 7, pp. 71-115, John Wiley and Sons, New York (1996)).

To date, there are three compounds used to generate 15 HNO in solution. One compound, Angeli's salt, which is the standard HNO source (Fukuto et al., J. Pharm. Exp. Ther. 263: 546-551 (1992)), is, of course, an inorganic salt. The other two compounds, acetylated Piloty's acid 20 (Smith et al., J. Amer. Chem. Soc. 82: 5731-5740 (1960)) and benzoylated hydroxycyanamide (Lee et al., J. Med. Chem. 35 3648-3652 (1992)) are promising inhibitors of aldehyde dehydrogenase. However, even in these compounds, there is debate as to whether the observed 25 physiological effects are attributed to NO, or to NO^- . For example, Piloty's acid has been shown to release NO oxidatively under physiological conditions (Zamora et al., Biochem. J. 312: 333-339 (1995)).

Reports that superoxide dismutase can prolong the 30 effects of NO via its reversible reduction to NO^- (Murphy et al., PNAS USA 88: 10860-10864 (1991)) and that NO^- , itself, exhibits potent activity as a vasodilator (Fukuto et al., J. Pharm. Exp. Ther. 263: 546-551 (1992)) and as 35 an inhibitor of aldehyde dehydrogenase (Lee et al., J. Med. Chem. 35: 3648-3652 (1992)) suggest that compounds, which release either NO or NO^- or mixtures of the two, are potentially useful pharmaceutical agents and may even offer advantages over compounds that just release NO.

Despite the extensive literature available on NO and nitric oxide-releasing compounds, there remains a need for stable nitric oxide-releasing compounds in which the nitric oxide-releasing group $N_2O_2^-$ is bonded directly to a 5 carbon atom and which can be prepared from compounds that do not include a nitrogen atom suitable for conversion to a diazeniumdiolate.

Accordingly, it is an object of the present invention to provide a chemical structural framework 10 having an atomic and electronic arrangement such that an $N_2O_2^-$ functional group attached thereto will serve as a spontaneous NO and/or NO^- donor. It is a further object of the present invention to provide a method for producing novel NO and/or NO^- -releasing diazeniumdiolates 15 in which the $N_2O_2^-$ group is bound to a carbon atom.

Another object of the present invention is to provide NO- and/or NO^- -releasing derivatives of amidines and enamines. A related object of the present invention is to provide NO- and/or NO^- -releasing derivatives of known 20 pharmaceutical agents. A more specific object is to provide NO- and/or NO^- -releasing derivatives of known pharmaceutical agents whose nitrogen atoms do not provide suitable N-diazeniumdiolates as nitric oxide donors. Yet another object of the present invention is to provide 25 compositions comprising NO- and/or NO^- -releasing derivatives of amidines and enamines. A further object of the present invention is to provide methods of using NO- and/or NO^- -releasing derivatives of amidine and enamine compounds, and compositions thereof. These and 30 other objects of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.


BRIEF SUMMARY OF THE INVENTION

35 The present invention provides NO- or NO^- -releasing diazeniumdiolates which are derived from an enamine or an amidine and in which the $N_2O_2^-$ functional group is bonded

to a carbon atom. The present invention also provides compositions comprising such diazeniumdiolate compounds, and methods of using such compounds and compositions. The present invention further provides a method of 5 producing an NO- or NO⁻-releasing enamine- or amidine-derived diazeniumdiolate. Additionally, the present invention provides a method for the preparation of an NO- and/or NO⁻-releasing amidine derivative from an existing 10 amino compound. The method comprises reaction of the amino compound with an acetamidating reagent followed by reaction with nitric oxide gas.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with one aspect of the invention, 15 there is provided a novel class of nitric oxide-nucleophile adducts or diazeniumdiolates having an amidine- or enamine-derived chemical linkage in which the N₂O₂⁻ functionality is bound directly to a carbon atom of the linkage. The amidine- or enamine-derived chemical 20 linkage which includes the N₂O₂⁻ functional group is represented by the schematic formula depicting the characteristic connectivity:



25


wherein

30 C²~C³ means either C²-C³ or C²=C³
 m is 1 or 2
 q is 0 or 1
 p is 0 or 1

provided that

- (1) C² is tetravalent, and bound to two or more of C¹, C³, N¹ and N²;
- 5 (2) when p=1, then q=0 and C²-C³ means C²-C³; or
- (3) when p=0, and q=1, then C²-C³ means either (i) C²=C³ or (ii) C²-C³ where C²-N¹ means C²=N¹;
- (4) when C²-C³ means C²-C³ and q=1 and p=0


10 C²-N¹ and C²-N² means



It will be appreciated by those skilled in the art that due to the nature of the synthesis reaction employed 15 as disclosed herein, the double bond in all cases would originally form as a C=N and then tautomerize if that is possible due to the presence of a C-H β to N¹. The double bond typically tautomerizes to the more thermodynamically favored structure. However, less thermodynamically 20 favored tautomers may occur and have been observed depending on conditions such as solvent or the like. In compounds where there is no H in the β position to N¹ no tautomerization occurs. Thus, the present invention contemplates all NO-releasing diazeniumdiolates which 25 include an amidine- or an enamine-derived chemical linkage in which the N₂O₂⁻ functional group is bound to a carbon atom irrespective of the tautomer that is thermodynamically favored. The electron movement or tautomerization for the enamines and for the amidines is 30 the same conceptually, but in the case of the enamines it is the lone pair of electrons associated with the nitrogen atom which must be used in the reaction since there is no H on the enamine nitrogen.


The amidine- and enamine-based diazeniumdiolates of the present invention are advantageous in several respects. These compounds are not expected to decompose to carcinogenic nitrosamines. The diazeniumdiolates of the present invention exhibit the full range of water solubility. Some of the diazeniumdiolates of the present invention are thus particularly useful where water insolubility is desirable, such as in stents, implants, prostheses and the like. Many diazeniumdiolates of the present invention are characterized by long-term slow release of NO and can be used in coatings or the like. Further, these compounds do not bleed out of the coating, even after the NO has been released. The diazeniumdiolates of the present invention are very stable solids and in solution are more heat stable than the previously described nitrogen analogs. Some can be recrystallized from boiling solvents without decomposition.

In keeping with the invention, the amidine-derived diazeniumdiolates may be further described in accordance with the following formulas:




25

FORMULA I,



FORMULA II, or



30

FORMULA III

wherein R¹-R⁵ can be a wide variety of substituents without departing from the scope of the present invention owing to the fact that any compound which includes the 5 characteristics of the chemical linkage identified above is contemplated herein.

Thus, in the compounds of Formula I, II or III, R¹-R³ are independently chosen from hydrogen, an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an 10 unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or unsubstituted C₃₋₈ cycloalkyl, a C₃₋₈ heterocyclic ring bound through a carbon atom and in 15 which the heteroatom is oxygen or nitrogen, a substituted or unsubstituted naphthyl, a substituted or unsubstituted tetrahydronaphthyl, a substituted or unsubstituted octahydronaphthyl, benzyl or substituted benzyl, substituted with up to three substituents, or a 20 substituted or unsubstituted phenyl, substituted with up to three substituents.

In the compounds of Formula I, II or III, R⁴ and R⁵ are independently hydrogen, an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or unsubstituted benzyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted piperazino, or a 25 substituted or unsubstituted morpholino. R⁴ and R⁵ also can be amino, an unsubstituted or substituted alkylamino, carboxyalkylamino, carboxydialkylamino, an unsubstituted or substituted tolyl, xylyl, anisyl, mesityl, nitro, an unsubstituted or substituted arylamino, an unsubstituted 30 or substituted dialkylamino, an unsubstituted or substituted diarylamino, an unsubstituted or substituted acetyl, an unsubstituted or substituted acetoxy, carboxy, 35

an unsubstituted or substituted carboxyalkyl, such as an unsubstituted or substituted carboxymethyl or an unsubstituted or substituted carboxyethyl, an unsubstituted or substituted alkylcarbonyl, thiol, an
5 unsubstituted or substituted alkylthio, an unsubstituted or substituted alkoxy, carboxamido, an unsubstituted or substituted alkylcarboxamido, an unsubstituted or substituted dialkylcarboxamido, an unsubstituted or substituted phenoxy, an unsubstituted or substituted
10 benzyloxy, an unsubstituted or substituted nitrophenyl, phenylcarbonyl, benzylcarbonyl, trialkylsilyl.

When any of the groups indicated above for R¹-R⁵ are identified as being substituted, such as when the C₁₋₁₂ straight chain alkyl, the C₃₋₁₂ branched chain alkyl, the
15 C₃₋₁₂ straight chain olefinic, the C₃₋₁₂ branched chain olefinic, the C₃₋₈ cycloalkyl, the benzyl, piperazino, morpholino, alkylamino, arylamino, acetyl, acetoxy, carboxy, carboxymethyl, alkoxy or the like are substituted, they can be substituted with any moiety that
20 does not destroy the NO-releasing character of the compounds and which, preferably, is biologically compatible. Accordingly, substituents to the substituted R¹-R⁵ groups can include hydroxy, alkoxy, acyloxy, halo or benzyl, acetyl, carboxyl, carboxyalkyl, such as
25 carboxymethyl, carboxyethyl, carboxyalkylamido, carboxydialkylamido, carboxamido, amino, alkylamino, dialkylamino, alkylcarbonyl, arylamino, diarylamino, cyano, toyl, xylyl, mesityl, anisyl, pyrrolidinyl, formyl, dioxane, thiol, alkylthiol, aryl, heteroaryl,
30 such as pyran, pyrrole, furan, thiophene, thiazole, pyrazole, pyridine, or pyrimidine, phenoxy, benzyloxy, phenylcarbonyl, benzylcarbonyl, nitrophenyl trialkylsilyl, nitro, sulfonyl, nitrobenzyl, trialkylammonium, alkyl, cycloalkyl, tetrahydrofuranyl,
35 tetrahydropyranyl, piperidinyl or morpholinyl.

The substituents R¹, R², R³, R⁴ and R⁵, in various combinations, and together with the nitrogen atom or

carbon atom to which they are bonded, can form unsubstituted or substituted cyclic or unsubstituted or substituted heterocyclic rings. The rings that are formed are four member rings or layers. For example, R¹ and R² together with the nitrogen atoms to which they are bonded can form a C₂₋₈ heterocyclic ring. R¹ and R⁴ together with the nitrogen atom to which R¹ is bonded and with the carbon atom to which R⁴ is bonded can form a C_{3-C₈} heterocyclic ring. Similarly, R² and R³ can form a C_{3-C₈} heterocyclic ring with the nitrogen atom to which they are bonded. The heterocyclic ring can also include up to one additional heteroatom, such as oxygen, nitrogen or sulfur.


The heterocyclic rings formed by the different combinations of R¹, R², R³, R⁴ and R⁵ can be, for example, a piperazino, a morpholino, a hexamethyleneimino, an imidazolyl, a pyrrolidino, a piperidino or the like. Likewise, R⁴ and R⁵ together with the carbon atom to which they are bonded can form a C₃₋₈ cycloalkyl, or a heterocyclic such as tetrahydrofuranyl, dioxanyl or the like. Further, R⁴ and R⁵ together with the carbon atom to which they are bonded can form a 1,4-benzodioxane, 1,3-benzodioxole, tetrahydronaphthlene, octahydronaphthalene, piperazine, morpholine, tetrahydroquinoline, tetrahydroquinoxaline, or tetrahydroisoquinoline.

Each of the cyclic or heterocyclic rings formed with R¹ and R², or R² and R³, or R¹ and R⁴, or R⁴ and R⁵ can be substituted with one or more substituents, including, by way of example, C_{3-C₈} cycloalkyl, alkoxy, benzyl, fused benzene, phenyl, an alkoxy, acetyl, carboxyl, carboxymethyl, carboxyethyl, carboxamido, amino, alkyl amino, dialkylamino, pyrrolidine, dioxane, thiol or alkylthiol, or a heteroaryl such as pyran, pyrrole, furan, thiophene, thiazole, pyrazole, pyridine, or pyrimidine.


The compounds of the present invention can be derived from existing pharmaceutical agents that contain

the amidine group. For example, a compound of Formula III preferably is one in which R¹ and R² are hydrogen and R³ is the entire substituent attached to an amine of a pharmaceutical agent such as, for example, tryptamine,
5 serotonin, histamine, valcyclovir, adenosine, thyroxine, guanine, guanosine, ubenimex, glucosamine, mannosamine, mycosamine, sphingosine, thienamycin, penicillamine and rimantadine. Similarly, for example, the present invention provides a compound of Formula III, in which R¹
10 and R² are hydrogen and R³ is the entire substituent attached to an amine of an amino acid. The amino acid is preferably lysine, tryptophan or hydroxy-trypophan.

The present invention also provides compounds of



FORMULA IV and



5

FORMULA V

wherein R¹-R⁶ can be a wide variety of substituents without departing from the scope of the present invention
 10 owing to the fact that any compound which includes the characteristics of the chemical linkage identified above is contemplated herein.

Thus, in the compounds of Formula IV and Formula V, R¹, R², R⁵ and R⁶ are independently hydrogen, an
 15 unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or unsubstituted benzyl, a
 20 substituted or unsubstituted piperazino, a substituted or unsubstituted morpholino, amino, an unsubstituted or substituted alkylamino, an unsubstituted or substituted arylamino, an unsubstituted or substituted dialkylamino, an unsubstituted or substituted diarylamino,
 25 carboxyalkylamino, carboxydialkylamino, cyano, tolyl, xylyl, anisyl, mesityl, nitro, an unsubstituted or substituted acetyl, an unsubstituted or substituted acetoxy, carboxy, an unsubstituted carboxyalkyl, such as an unsubstituted or substituted carboxymethyl, or an
 30 unsubstituted or substituted carboxyethyl, an

unsubstituted or substituted alkylcarbonyl, thiol, an unsubstituted or substituted alkylthio, an unsubstituted or substituted alkoxy, carboxamido, an unsubstituted or substituted alkylcarboxamido, or an unsubstituted or 5 substituted dialkylcarboxamido.

In the compounds of Formula IV and V, R³ and R⁴ are independently chosen from hydrogen, an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or 10 substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or unsubstituted C₃₋₈ cycloalkyl, a C₃₋₈ heterocyclic ring bound through a carbon atom and in which the heteroatom is oxygen or nitrogen, a substituted or unsubstituted 15 naphthyl, a substituted or unsubstituted tetrahydronaphthyl, a substituted or unsubstituted octahydronaphthyl, benzyl or substituted benzyl, substituted with up to three substituents, or a substituted or unsubstituted phenyl, substituted with up 20 to three substituents. Such compounds are advantageous because they are more "organic" than polyamines, such that simple aromatic enamines can be made to be water-insoluble, yet release NO, and to be heat-stable.

When any of the groups indicated above for R¹-R⁵ are 25 identified as being substituted, such as the C₁₋₁₂ straight chain alkyl, the C₃₋₁₂ branched chain alkyl, the C₃₋₁₂ straight chain olefinic, the C₃₋₁₂ branched chain olefinic, the C₃₋₈ cycloalkyl, the benzyl, piperazino, morpholino, alkylamino, arylamino acetyl, acetoxy carboxy, 30 carboxymethyl alkoxy or the like, they can be substituted with any moiety that does not destroy the NO-releasing character of the compounds and which, preferably, is biologically compatible. Accordingly, substituents to the substituted R¹-R⁵ groups can include hydroxy, alkoxy, 35 acyloxy, halo or benzyl, acetyl, carboxyl, carboxyalkyl, such as carboxymethyl, carboxyethyl, carboxyalkylamido, carboxydialkylamido, carboxamido, amino, alkyl amino,

dialkylamino, alkylcarbonyl, arylamino, diarylamino, tolyl, xylyl, mesityl, anisyl, pyrrolidine, formyl, dioxane, thiol, alkylthiol, aryl, heteroaryl, such as 5 pyran, pyrrole, furan, thiophene, thiazole, pyrazole, pyridine, or pyrimidine, phenoxy, benzyloxy, phenylcarbonyl, benzylcarbonyl, nitrophenyl trialkylsilyl, nitro.

The groups R¹-R⁶ of the compounds of Formula IV and Formula V in various combinations, and together with the 10 nitrogen atom or carbon atom to which they are bonded and intervening atoms, can form heterocyclic rings. For example, and not in limitation, a compound of Formula V in which R³ and R⁴, together with the nitrogen atom to which they are bonded, can form a C₃₋₈ heterocycle. The 15 heterocycle can be further substituted with a heteroatom. As another example, in the Formula V compound, R¹ and R⁶, together with the C=C-C through which they are bonded, can form a substituted or unsubstituted C₃₋₁₂ cycloalkyl. Similarly, for a compound of Formula IV, R² and R³, 20 together with the nitrogen to which R³ is bonded, can form a C₃₋₈ heterocycle. The heterocycle can be further substituted with a heteroatom, or an aromatic ring, which can be substituted with a C₁₋₆ alkyl or a C₁₋₆ alkoxy. Also, R⁵ and R⁶ can form a C₃₋₈ heterocycle, which can also 25 be substituted.

In Formulas IV and V, R³ and R⁴ together with the nitrogen atom to which they are bonded can form a C₃₋₈ heterocyclic ring or a C₃₋₈ substituted heterocyclic ring or a C₃₋₈ unsubstituted or substituted heterocyclic ring 30 containing up to two additional heteroatoms selected from the group O, S, N.

Also, R⁵ and R⁶ together with the carbon to which they are bonded can form a substituted or unsubstituted C₄₋₈ cycloalkyl.


35 With respect to the compounds of Formulas I, II and III, R¹-R⁵ can be selected such that they represent the substituents attached to the amidine of nasal

decongestants and α -adrenergic antagonists such as tetrahydrozoline, idazoxan, phentolamine, xylometazoline and the like.

In accordance with another aspect of the invention,
5 there is provided a method for the preparation of the
amidine- and enamine-derived NO-releasing compounds
described herein. In one embodiment, the method
comprises reacting an amidine, preferably an amidine of
Formula Ia, IIa or IIIa, with gaseous NO in acetonitrile
10 or a similar solvent to produce an $N_2O_2^-$ -containing
compound. R^1 and R^4 together with the nitrogen atom to
which R^1 is bonded and with the carbon atom to which R^4 is
bonded can form a C_3-C_8 heterocyclic ring.

The solvent is preferably chosen so that the starting amidine or enamine is soluble whereas the resulting N_2O_2^- -containing product is insoluble and so precipitates as it forms in order to drive the reaction to completion. Anhydrous and neutral solvents such as acetonitrile, tetrahydrofuran, dioxane and ether are preferred because they do not cause hydrolysis of the water-sensitive amidines and enamines. However, it is anticipated that low yields of the desired products can also form in partly aqueous and/or basic solvents such as NaOMe in methanol or wet tetrahydrofuran among others, and such solvents may also be used.


The resulting compound in accordance with the method of the invention contains either one or two N_2O_2^- functional groups depending upon the structure of the amidine reactant, as, for example, shown below.



Ia

I

17




5

10 Methods for the preparation of the amidines, such as those of Formulas Ia, IIa and IIIa, are well known and have been reviewed in two reference books, Gautier et al., "Preparation and Synthetic Uses of Amidines," Chapter 7 in The Chemistry of Amidines and Imidates,
 15 Editor: Patai, pp. 283-348, Wiley, 1975, and Boyd, "Recent Advances in the Synthesis of Amidines," Chapter 7 in The Chemistry of Amidines and Imidates, Volume 2, Editors: Patai and Rappoport, pp. 339-367, Wiley, 1991. These methods can be used by those skilled in the art to
 20 prepare a wide variety of amidines which can then be made into NO-releasing diazeniumdiolates in accordance with the invention.

By way of example and not in limitation, the preparation of an NO-releasing amidine-derived diazeniumdiolate can be illustrated by the reaction of 2-methyl-2-imidazoline with NO as follows:


18




Although the initial reaction products are the amidinium salts (either intramolecular or intermolecular), standard metathesis reactions can be employed to change the cation to any pharmaceutically acceptable ion. This is illustrated above by the reaction involving sodium methoxide in methanol, which produces the disodium salt. Also, by varying the synthesis procedures, the intramolecular or intermolecular salt or a mixture thereof can be obtained; the reaction of 2-methyl-2-imidazoline with NO in NaOMe/MeOH to directly form the sodium salt is an example of such a reaction.

While applicants do not wish to be bound to any particular theory, the above reactions are believed to be explained by the reaction of NO with the little exploited enediamine tautomers of the amidines. The enediamine tautomers are known to exist in solution and were first proposed to explain deuterium exchange in NMR solutions as follows (Isagulyants et al., Zh. Prikl. Khim. 41: 1585-1590 (1968); also, in Chem. Abstracts 70: 11629h (1969)):

19



Accordingly, while not being bound to any particular theory, it is believed that the reaction of the above undeuterated compound with an NO dimer is as follows:




10


The reaction is believed to stop at this stage due to steric hindrance and/or precipitation of the product from solution.

When either the amidinium or sodium salt of the NO-releasing diazeniumdiolate derived from 2-methyl-2-imidazoline was dissolved in water and acidified, a voluminous gas evolution resulted and the solution turned blue in color and remained so for many hours after gas evolution had ceased. When the experiment was repeated at pH 7.4, the evolving gas was identified as a mixture of 2 parts NO (determined by chemiluminescence) and 1

part N₂O (determined by gas chromatography). Nitrous oxide (N₂O), being the end product of HNO dimerization and dehydration, provided a measure of HNO production via the equation (Nagasawa et al., J. Med. Chem. 33: 3122-3124
5 (1990)):




10 Again, while not wishing to be bound to any particular theory, it is believed that the partial mechanistic explanation for these observations is as follows:




The last step in this mechanism is not well understood but has precedent in the known release of NO by FK409 and closely related compounds which are used as standard sources of NO (Kita et al., *Eur. J. Pharmacol.* 257: 123-130 (1994)). Although this mechanism is one explanation for the observed NO and N₂O release, it is a

very incomplete representation of what actually happens to any given compound in aqueous solution. Specifically, amidines are known to be subject to hydrolysis at rates that range from very slow, such as for 2-methyl-2-imidazoline (Haake et al., J. Org. Chem. 35: 4063-4067 (1970))



to very fast for acetamidine (Davies et al, Chem. Ind. (London): 628 (1958)).




Thus, at any intermediate stage of HNO or NO release, the amidino group could hydrolyze and no further gas would be generated. A compound in which the amidine hydrolyzes rapidly would release much HNO but very little NO, whereas a compound in which the amidine hydrolyzes slowly would have time for NO release, which is the last step, and would thus release a larger amount of NO. In this regard, compounds of Formula I (as set forth above) cannot be hydrolyzed by the above mechanism. It is believed that these mono-N₂O₂⁻ derivatives break down via two competing pathways, one of which appears to be simple reversal of the synthesis step to release NO, while the other may be a single scission to yield one molecule of HNO and a mono-C-nitroso compound. Since the amidino tautomers cannot come into conjugation with this nitroso group, it does not serve as a source of NO, and since hydrolysis of the amidine competes with the first

pathway, compounds derived from amidines of formula I release only small amounts of NO, but over a long period of time. In such cases, the reaction of an amidine with NO results in a sterically hindered compound of formula 5 I, which is apparently inclined to break apart differently than previously reported, less hindered $N_2O_2^-$ compounds.

In another embodiment of the present inventive method, an enamine, preferably an enamine of Formula IV 10 or V, is reacted with NO to produce an $N_2O_2^-$ containing compound. Enamines are prepared from an equimolar mixture of an aldehyde or ketone and a secondary amine via dehydration as follows.


15



Methods for preparing enamines and lengthy discussions of their properties are readily available to synthetic chemists (see, e.g., Hickmott, Tetrahedron 38: 20 1975-2050 (1982); Hickmott, Tetrahedron 38: 3363-3446 (1982); Cook, Enamines: Synthesis, Structure and Reactions, Marcel Dekker, New York (1988); and Szmuszkovicz, Enamines, Vol. 4 of Adv. in Org. Chem. Methods and Results, Wiley Interscience, New York (1963)). Although literally thousands of carbonyl compounds are used in this reaction, the amines are usually limited to a select few, such as dimethylamine, diethylamine, piperidine, pyrrolidine, morpholine, and N-methylaniline.

Unlike the amidine-derived compounds, the enamine-derived diazeniumdiolates do not appear to release any NO^- or N_2O . Rather, they release small amounts of NO over prolonged periods of time (e.g., 1 week in phosphate-buffered saline). As with amidine-derived compounds, the

mechanism of NO release is complicated by a competing hydrolysis mechanism as set forth below.



- It will be appreciated by those of ordinary skill in
 5 the art that either the amidine-derived or enamine-
 derived diazeniumdiolates in accordance with the present
 invention can be formed as a salt, and preferably, a
 biologically acceptable salt. Accordingly, the
 counterion is preferably any biologically acceptable
 10 acceptable counterion. Such counterions can include, but
 are not limited to, sodium ion, potassium ion, quaternary
 ammonium ions, and the like.

Also provided by the present invention is a method
 of producing a nitric oxide-releasing compound from a
 15 compound containing a primary amine and/or a secondary
 amine. The method comprises (a) treating the compound
 containing a primary amine and/or a secondary amine with
 an acetamidating agent, by which is meant an organic
 chemical reagent capable of transferring the $\text{CH}_3\text{C}(=\text{NH})^-$
 20 group from itself to another molecule. Such reagents are
 generally acetimidates, for example, ethyl acetimidate,
 or thioimidates, for example, benzyl thioacetimidate.
 The preferred reagent for use in the context of this
 method is that described in Shearer et al., Tetrahedron
 25 Letters 38(2): 179-182 (1997), so as to form an
 acetamidine derivative of the compound containing the
 primary amine and/or secondary amine, and (b) treating
 the acetamidine derivative with nitric oxide gas to form

an amidine-derived diazeniumdiolate. This method in accordance with the invention provides a method for preparing an amidine-based diazeniumdiolate in which the NO-releasing N_2O_2^- functional group is bound to a carbon atom rather than to the original primary or secondary amine. In this way, many primary and secondary amine-containing drugs can be subjected to the acetamidating reagent to produce the amidine which can then be converted to the diazeniumdiolate. This is advantageous particularly in the case of primary amines where the $\text{N}-\text{N}_2\text{O}_2^-$ functionality is not very stable.

As is well known in the art, nitric oxide and compounds comprising N_2O_2^- functional groups can have a wide range of utilities, in part because of the multifaceted role of nitric oxide in bioregulatory processes. Accordingly, the present invention also provides a composition, including a pharmaceutical composition, comprising a present inventive diazeniumdiolate. Preferably, the pharmaceutical composition additionally comprises a pharmaceutically acceptable carrier.

One skilled in the art will appreciate that suitable methods of administering a diazeniumdiolate composition of the present invention to an animal, such as a mammal, are available, and, although more than one route can be used to administer a particular composition, a particular route can provide a more immediate and more effective reaction than another route. Pharmaceutically acceptable carriers are also well-known to those who are skilled in the art. The choice of carrier will be determined, in part, both by the particular composition and by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of the pharmaceutical compositions of the present invention.

Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective

amount of the diazeniumdiolate dissolved in diluents, such as water or saline, (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules, (c) suspensions 5 in an appropriate liquid, and (d) suitable emulsions. Solutions may also be formulated using known preservatives for amidine-based nasal decongestants.

Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline 10 cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible 15 carriers. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like. 20 containing, in addition to the active ingredient, such carriers as are known in the art.

The diazeniumdiolates of the present invention, alone or in combination with other suitable components, can be made into aerosol formulations to be administered 25 via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

Formulations suitable for parenteral administration include aqueous and non-aqueous solutions, isotonic 30 sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, 35 solubilizers, thickening agents, stabilizers, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as

ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous 5 injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

The dose administered to an animal, particularly a human, in the context of the present invention should be 10 sufficient to effect a therapeutic response in the animal over a reasonable time frame. The dose will be determined by the strength of the particular compositions employed (taking into consideration, at least, the rate of NO evolution, the extent of NO evolution, and the 15 bioactivity of any decomposition products derived from the diazeniumdiolates) and the condition of the animal, as well as the body weight of the animal to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects 20 that might accompany the administration of a particular composition. A suitable dosage for internal administration is 0.01 to 100 mg/kg per day. A preferred dosage is 0.01 to 35 mg/kg per day. A more preferred dosage is 0.05 to 5 mg/kg per day. A suitable 25 concentration of a enamine- or amidine-derived diazeniumdiolate in pharmaceutical compositions for topical administration is 0.05 to 15% (by weight). A preferred concentration is from 0.02 to 5%. A more preferred concentration is from 0.1 to 3%.

30 In view of the above, the present invention provides methods of using a nitric oxide-releasing amidine- or enamine-derived diazeniumdiolate. In one embodiment, a method of treating an animal, such as a mammal, with a biological disorder treatable with nitric oxide, is 35 provided. The method comprises administering to the animal, e.g., the mammal, in need thereof an amount of an enamine- or amidine-derived diazeniumdiolate sufficient

to treat the biological disorder in the animal. In this embodiment, "biological disorder" can be any biological disorder, including hypertension, restenosis, impotency, and a biological disorder due to a genetic defect or
5 infection with an infectious agent, such as a virus, bacterium or parasite, as long as the disorder is treatable with nitric oxide.

With regard to the above, NO- and/or NO⁻-releasing compounds derived from amidines are advantageous inasmuch
10 as amidines are present in many already approved medicinal agents, e.g., tranquilizers, α -adrenergic antagonists, like phentolamine, and nasal decongestants. Specific examples include tolazoline and diazoxide. Other examples of amidine-containing compounds include
15 methyl pyrimidine and 1,8-diamino octahydronaphthalene.

In another embodiment of a method of use, a method is provided for treating an animal, such as a mammal, for infection with, for example, a virus, a bacterium, or a parasite. The method comprises administering to the
20 animal, e.g., the mammal, an amount of a diazeniumdiolate sufficient to treat the infection in the animal.

In yet another embodiment, a method for treating an animal, such as a mammal, for cancer is provided. The method comprises administering to the animal, e.g., the
25 mammal, an amount of diazeniumdiolate sufficient to prevent the growth or metastasis of the cancer in the animal or to render it more susceptible to radiation or chemotherapy.

In another embodiment, a method is provided for
30 treating an inanimate object for the presence of a potentially infectious virus, bacterium, or parasite. The method comprises contacting the inanimate object with an amount of a present inventive diazeniumdiolate sufficient to reduce the presence of the potentially
35 infectious virus, bacterium or parasite. By "potentially infectious" is meant the capability of infecting an animal, such as a mammal.

It is contemplated that the diazeniumdiolates derived from enamines and amidines in accordance with the present invention can be used to coat prostheses, stents, and medical implants, such as breast implants, prior to 5 surgical introduction into the body as a means of reducing the risk of solid state carcinogenesis associated therewith, or as a means of preventing adhesion of platelets to the implants. Additionally, the prostheses and implants can be manufactured using an 10 enamine- or amidine-derived diazeniumdiolate as an integral component of the starting materials. Medical devices incorporating an enamine- or amidine-derived diazeniumdiolate provide an invaluable two-pronged approach to the treatment of many biological disorders, 15 providing useful medical structures that also advantageously provide local release of NO.

The diazeniumdiolates derived from enamines and amidines also have utility in the *in vitro* study of NO biology.

20

EXAMPLES

The following examples further illustrate the present invention and, of course, should not be construed as in any way limiting its scope.

25 All melting points were determined on a hot stage and are uncorrected. The ^1H NMR spectra were determined at 200 MHz with a Varian XL-200 spectrometer and the ^{13}C NMR spectra were obtained at 50 MHz using the same instrument. The chemical shifts are expressed in δ values (ppm) relative to either tetramethylsilane or 30 sodium 3-(trimethylsilyl)propionate-d₄ as internal standards. Elemental analyses were performed by Atlantic Microlabs, Inc. (Norcross, GA).

Except as noted here, all reagents and amines were 35 obtained from Aldrich Chemical Company (Milwaukee, WI). Reaction solvents were Aldrich anhydrous grade but all others were reagent grade. Commercial grade nitric oxide

was obtained from Matheson Gas Products and was used as received.

Reactions under pressure were conducted in standard glass hydrogenation bottles as previously described
5 (Hrabie et al., J. Org. Chem. 58: 1472-1476 (1993)). The general directions are repeated here for completeness.

Given that stainless steel (SS) is required for prolonged exposure to NO gas and amines degrade most
10 types of stoppers and gaskets, a specialized reactor modeled after the standard Parr 3911 hydrogenation apparatus (Parr Instrument Co., Moline, IL) was constructed. The reservoir was replaced by a type 304 SS gas sampling cylinder equipped with SS fittings
15 (available from any "valve and fitting" plumbing supply company). The valves were diaphragm-seal packless type (Aldrich), and the pressure gauges were SS (Air Products). The usual Parr clamp and bottle system was employed but was connected to the gas reservoir via a
20 Teflon tube and mounted to allow stirring with a magnetic stirrer.

All of the analytical data given were obtained using the products as isolated directly from the reaction mixtures.
25

EXAMPLE 1

This example describes a generalized procedure for the preparation of NO- and/or NO⁻-releasing compounds from amidines.

30 A solution of the appropriate amidine, which was obtained commercially (Aldrich) or synthesized in accordance with standard procedures, in the desired solvent was placed in a standard Parr hydrogenation bottle. Nitrogen was passed through the apparatus and
35 bubbled through the solution for 5-10 min, the bottle was clamped, and NO gas was admitted to a pressure of 5 atm. The solution was stirred for the indicated time at room

temperature with addition of NO as needed during the first 5-6 h to maintain the reservoir pressure. Excess NO was then vented and N₂ was bubbled through the resultant white slurry for 5 min. The product was 5 isolated by filtration, washed with the reaction solvent, then washed with ether and dried *in vacuo* for several hours. All of the products were amorphous, voluminous white powders, which were air-stable but were stored in a refrigerator.

10

EXAMPLE 2

This example describes the preparation of 2-methyl-2-imidazoline tetrakis(nitric oxide)adduct and its sodium salt.

15 A solution of 2-methyl-2-imidazoline (lysidine, 5.0 g, 59.4 mmol) in 150 ml acetonitrile was reacted with NO for 28 h as described above. Yield 3.59 g (49%); m.p. 102-103 °C dec.; ¹H NMR (D₂O) δ 1.92 (6H, s), 3.51 (8H, s), 3.67 (4H, s); ¹³C NMR (D₂O) 24.8, 42.4, 42.5, 44.6, 20 51.3, 51.7, 163.5, 177.2; UV (0.01 N NaOH) λ_{max} 260 nm, = 13,600 M⁻¹cm⁻¹, 206 nm, ε = 22,500. Anal. Calcd for C₁₂H₂₄N₁₀O₄: C, 38.71; H, 6.50; N, 37.61. Found: C, 38.92; H, 6.55; N, 37.62.

To prepare the disodium salt, 1.74 g of a 25% NaOMe 25 in MeOH solution (Aldrich, 8.06 mmol) was diluted with 0.5 ml MeOH and to this was added 1.5 g of the above diimidazolinium salt (8.06 mmol). The solid slowly dissolved and then re-precipitated. The slurry was diluted with acetonitrile, filtered and the solid dried 30 *in vacuo* to afford a white powder. Yield 0.92 g (92%). m.p. >180 °C (chars); ¹H NMR (D₂O) δ 2.7-2.8 (2H, m), 3.3-3.4 (2H, m).

EXAMPLE 3

35 This example describes the preparation of acetamidine tetrakis(nitric oxide)adduct.

A solution of acetamidine hydrochloride (7.0 g, 74.0 mmol) in 150 ml acetonitrile was treated with 16.93 ml of 25% NaOMe in MeOH (74.0 mmol) and the precipitated sodium chloride was removed by filtration. The resulting 5 solution was treated with NO for 16 h to yield a tan powder. Yield 5.95 g (82%); m.p. >150 °C (chars); ¹H NMR (D₂O) δ 2.21 (s); ¹³C NMR (D₂O) 20.8, 51.8, 57.7, 164.6.

EXAMPLE 4

10 This example describes the preparation of 2-iminopiperidine bis(nitric oxide) adduct.

A solution of 2-iminopiperidine hydrochloride (5.0 g, 37.2 mmol) in 200 ml acetonitrile was treated with 8.5 ml of 25% NaOMe in MeOH (37.2 mmol) and 10 ml MeOH and 15 the precipitated sodium chloride was removed by filtration. The resulting solution was treated with NO for 23 h to yield an off-white powder. Yield 4.5 g (95%); m.p. 110-112 °C (dec.); ¹H NMR (D₂O) δ 1.8-1.9 (6H, m), 2.55-2.65 (2H, m), 2.85-2.95 (2H, m), 3.3-3.4 (2H, m), 3.5-3.6 (2H, m); ¹³C NMR (D₂O) 19.0, 20.3, 23.0, 28.3, 20 29.0, 43.7, 44.1, 90.6, 100.5, 162.6.

EXAMPLE 5

25 This example describes the preparation of 2-cyclohexyl-2-imidazoline bis(nitric oxide) adduct.

The starting material for this preparation was produced by the method described by Neef et al. (J. Org. Chem. 46: 2824-2826 (1981)). A solution of 2-cyclohexyl-2-imidazoline (5.0 g, 32.8 mmol) in 300 ml acetonitrile 30 was reacted with NO for 78 h. Yield 6.66 g (97%); m.p. 158-159 °C (dec.); ¹H NMR (D₂O) δ 1.4-1.7 (6H, m), 1.9-2.1 (2H, m), 2.5-2.6 (2H, m), 4.0 (4H, s); ¹³C NMR (D₂O) 23.9 (2C), 26.6, 34.3 (2C), 47.3 (2C), 73.0, 173.4.

35 EXAMPLE 6

This example describes the preparation of tetrahydrozoline bis(nitric oxide) adduct.

A solution of tetrahydrozoline hydrochloride (10.0 g, 42.25 mmol) in 9.66 ml of 25% NaOMe in MeOH (42.25 mmol NaOMe) was diluted with 200 ml acetonitrile and the precipitated sodium chloride was removed by filtration.

5 The resulting solution was treated with NO for 24 h. Yield 9.0 g (82%); m.p. 168-169 °C (dec.); ¹H NMR (D₂O) δ 1.8-1.9 (2H, m), 2.3-2.45 (1H, m), 2.9-3.0 (3H, m), 4.00 (4H, s), 7.15-7.47 (4H, m); ¹³C NMR (D₂O) 20.4, 30.6, 34.7, 47.7 (2C), 76.0, 129.7, 130.7, 131.8, 133.0, 133.1, 10 141.5, 173.7. Anal. Calcd. for C₁₃H₁₆N₄O₂: C, 59.99; H, 6.20; N, 21.52. Found: C, 60.05; H, 6.14; N, 21.48.

EXAMPLE 7

This example describes the preparation of idazoxan-15 bis(nitric oxide) adduct available from Research Biochemicals, Inc. (Natick, MA).

A solution of idazoxan hydrochloride (1.00 g, 4.155 mmol) in a mixture of 0.95 ml 25% NaOMe in MeOH (4.155 mmol NaOMe) and 3 ml MeOH was diluted with 40 ml 20 acetonitrile and the precipitated sodium chloride was removed by filtration. The resulting solution was treated with NO for 21 h. Yield 0.62 g (56%); m.p. 152-154 °C (dec.); ¹H NMR (D₂O) δ 4.04 (4H, s), 4.64 (1H, d), 5.13 (1H, d), 7.02-7.22 (4H, m). Anal. Calcd. for 25 C₁₃H₁₆N₄O₂: C, 49.81; H, 4.94; N, 21.12. Found: C, 50.22; H, 4.61; N, 20.98.

EXAMPLE 8

This example describes a general procedure for 30 preparation of diazeniumdiolate derivatives of enamines.

Enamines were prepared from an equimolar mixture of an aldehyde and ketone and a wide variety of secondary amines via dehydration. Such methods are described in Hicknott, Tetrahedron 38: 1975-2050, and 3363-3446 35 (1982); Cook, Enamines: Synthesis, Structure and Reactions, Marcel Dekker, New York (1988); and Szmuszkovicz, "Enamines", Chapter 4, In advances in Org.

Chem. Methods and Results, Wiley Interscience, New York (1963). Preferred amines include dimethylamine, diethylamine, piperidine, pyrrolidine, morpholine and N-methyl-aniline.

5 These compounds were prepared according to the general procedure set forth in Example 1, except that the reactions were cooled when required and some gave crystalline products as indicated in the individual descriptions.

10

EXAMPLE 9

This example describes the preparation of cyclohexanone morpholine enamine bis(nitric oxide) adduct.

15 A solution of the enamine derived from morpholine and cyclohexanone (15.0 g, 89.7 mmole) in 150 ml ethyl ether was cooled in dry ice without stirring and reacted with NO for 20 h as it warmed to room temperature.

Workup as above produced large clear crystals of product.

20 Yield 8.14 g (40%); m.p. 85-87 °C; ¹H NMR (CD₃CN) δ 1.5-2.3 (6H, m), 2.44-2.55 (4H, m), 2.85-2.96 (4H, m), 5.13-5.18 (1H, m), 5.23-5.27 (1H, t), 11.6 (1H, br.s); ¹³C NMR (CD₃CN) 19.2, 24.7, 28.6, 50.6 (2C), 67.1, 67.5 (2C), 112.5, 141.3; exact mass calcd. for C₁₀H₁₇N₃O₃ (M⁺)

25 227.1269, found 227.1254. Anal. Calcd. for C₁₀H₁₇N₃O₃: C, 52.85; H, 7.54; N, 18.49. Found: C, 53.32; H, 7.63; N, 18.76.

EXAMPLE 10

30 This example describes the preparation of isobutyraldehyde morpholine enamine bis (nitric oxide) adduct.

A solution of the enamine derived from morpholine and isobutyraldehyde (7.0 g, 49.6 mmole) in 100 ml THF 35 was reacted with NO for 22 h as described above. Yield 4.05 g (41%); m.p. 91-92 °C; ¹H NMR (D₂O) δ 1.48 (6H, s), 3.25-3.31 (4H, m), 3.92-3.98 (4H, m), 5.26 (1H, s); ¹³C

NMR (D_2O) 23.2 (2C), 46.1 (2C), 66.6 (2C), 75.7, 95.2; exact mass calcd. for $C_8H_{16}N_3O_3$ (MH^+) 202.1192; found 202.1137. Anal. Calcd. for $C_8H_{15}N_3O_3$: C, 47.75; H, 7.51; N, 20.88. Found: C, 47.74; H, 7.70; N, 20.13.

5

EXAMPLE 11

This example describes the preparation of cyclohexanecarboxaldehyde morpholine enamine bis (nitric oxide) adduct.

10 A solution of 4-(cyclohexylidenemethyl)morpholine (10.0g, 55.2 mmol) in 200mL of CH_3CN was cooled at 0°C in an ice bath and reacted without stirring with NO as described above for 6 h and then warmed to room temperature. The product was isolated by filtration, 15 washed with CH_3CN , then ether and dried *in vacuo*. Yield 7.13g (54%); mp 115-117°C; 1H NMR δ 1.25-1.40 (2H, m), 1.48-1.70 (4H, m), 1.95-2.40 (4H, m), 3.20-3.26 (4H, m), 3.90-3.96 (4H, m), 5.05 (1H, s); ^{13}C NMR δ 24.1 (2C), 27.8, 31.3 (2C), 46.3 (2C), 67.1 (2C), 78.0, 95.7. 20 Anal. Calcd for $C_{11}H_{19}N_3O_2$: C, 54.76; H, 7.94; N, 17.41. Found: C, 54.93; H, 8.04; N, 17.60.

EXAMPLE 12

This example describes the preparation of 25 isobutyraldehyde piperidine enamine bis(nitric oxide) adduct (25).

A solution of the enamine derived from piperidine and isobutyraldehyde (5.0 g, 35.9 mmole) in 150 ml CH_3CN was stirred at room temperature and reacted with NO for 30 23 h as described above. Yield 3.25 g (45%); m.p. 84-85 °C; 1H NMR (D_2O) δ 1.48 (6H, s), 1.66-1.83 (6H, m), 3.13-3.18 (4H, m), 5.25 (1H, s). ^{13}C NMR (D_2O) 23.2 (2C), 24.3, 25.1 (2C), 47.4 (2C), 75.5, 95.2. Anal. Calcd. for $C_9H_{17}N_3O_2$: C, 54.25; H, 8.60; N, 21.09. Found: C, 52.69; 35 H, 8.56; N, 21.28.

EXAMPLE 13

This example describes the preparation of isobutyraldehyde pyrrolidine enamine bis (nitric oxide) adduct.

5 A solution of N-(2-methyl-1-propenyl)pyrrolidine (10.0g, 79.9 mmol) in 200 mL of CH₃CN was cooled to 0°C in an ice bath and reacted without stirring with NO as described above for 6 h and then warmed to room temperature. The product was isolated by filtration, 10 washed with CH₃CN, then ether and dried *in vacuo*. Yield 88.8g (60%); mp 75-76°C; ¹H NMR δ 1.48 (6H, s), 1.98-2.03 (4H, m), 3.23-3.32 (4H, m), 5.25 (1H, s); ¹³C NMR δ 23.2 (2C), 26.5 (2C), 48.3 (2C), 75.6, 95.2.

15 EXAMPLE 14

This example describes the preparation of isobutyraldehyde N-methylaniline enamine bis(nitric oxide) adduct.

20 A solution of the enamine derived from N-methylaniline and isobutyraldehyde (5.0 g, 31.0 mmole) in 150 ml CH₃CN was stirred at room temperature and reacted with NO for 20 h. The resulting pale yellow solution was concentrated to dryness on a rotary evaporator and the residual solid was recrystallized from absolute ethanol 25 to yield 2.26 g (33%) of product as pale, cream-colored needles. m.p. 83-84 °C; ¹H NMR (CDCl₃) δ 1.59 (3H, s), 1.63 (3H, s), 2.75 (3H, s), 6.00 (1H, s), 6.96-7.37 (5H, m); ¹³C NMR (CDCl₃) 17.4, 26.8, 34.4, 75.6, 101.1, 118.9 (2C), 122.7, 129.4 (2C), 149.3. Anal. Calcd. for 30 C₁₁H₁₅N₃O₂: C, 59.71; H, 6.83; N, 18.99. Found: C, 59.77; H, 6.84; N, 19.01.

EXAMPLE 15

35 This example describes the preparation of isobutyraldehyde N-methyl-p-toluidine enamine bis(nitric oxide) adduct.

A solution of the enamine derived from N-methyl-p-toluidine and isobutyraldehyde (5.0 g, 28.5 mmole) in 150 ml CH₃CN was stirred at room temperature and reacted with NO for 20 h. The resulting pale yellow-orange solution 5 was concentrated to dryness on a rotary evaporator and the residual off-white solid was recrystallized from absolute ethanol to yield 2.21 g (33%) of product as white cotton-like needles. m.p. 127-128 °C; ¹H NMR (CDCl₃) δ 1.58 (3H, s), 1.61 (3H, s), 2.31 (3H, s), 2.71 10 (3H, s), 5.92 (1H, s), 6.90-7.15 (4H, m); ¹³C NMR (CDCl₃) 17.3, 20.5, 26.8, 34.9, 75.4, 101.9, 119.7 (2C), 129.9 (2C), 132.7, 147.2. Anal. Calcd. for C₁₂H₁₇N₃O₂: C, 61.26; H, 7.28; N, 17.86. Found: C, 61.32; H, 7.35; N, 17.88.

15 EXAMPLE 16

This example describes the preparation of isobutyraldehyde N-methyl-p-anisidine enamine bis (nitric oxide) adduct.

A solution of the enamine derived from N-methyl-p-anisidine and isobutyraldehyde (5.0 g, 26.1 mmole) in 150 ml CH₃CN was stirred at room temperature and reacted with NO for 23 h. The resulting pale brown solution was 20 concentrated to dryness on a rotary evaporator and the residual oil was crystallized from absolute ethanol to 25 yield 4.89 g (75%) of product as colorless chunky crystals. m.p. 97-98 °C; ¹H NMR (CDCl₃) δ 1.58 (3H, s), 1.60 (3H, s), 2.67 (3H, s), 3.79 (3H, s), 5.80 (1H, s), 6.84-7.06 (4H, m); ¹³C NMR (CDCl₃) 17.2, 26.8, 36.1, 55.5, 75.2, 103.0, 114.6 (2C), 122.8 (2C), 143.4, 156.3. Anal. 30 Calcd. for C₁₂H₁₇N₃O₃: C, 57.35; H, 6.82; N, 16.72. Found: C, 57.36; H, 6.87; N, 16.75.

EXAMPLE 17

This example describes the measurement of the 35 production of NO and N₂O by amidine/nitric oxide adducts.

As a demonstration of the efficacy of the amidine/nitric oxide adducts described herein as nitric

oxide and nitroxyl releasing agents, selected compounds were dissolved in either 0.1 N HCl or pH 7.4 buffer and the headspace was monitored by chemiluminescence (to detect NO) and gas chromatography (to detect N₂O, the 5 dehydrated dimer of HNO). The results are shown in Table I.

Table I

| Cmpd of Ex. No. | Solution | Ratio N ₂ O:NO | <u>Yield (in moles per</u> <u>mole cmpd)</u> | |
|--------------------|-----------|------------------------------|---|-------|
| | | | N ₂ O | NO |
| 2 | 0.1 N HCl | 2:1 | 0.9 | 0.45 |
| 3 | pH 7.4 | 13:1 | 0.64 | 0.05 |
| 4 | pH 7.4 | 6:1 | 0.45 | 0.08 |
| 5 | 0.1 N HCl | --- | 0.2 | N.D.* |
| 6 | pH 7.4 | --- | 0.4 | N.D.* |

10

*The compounds of Examples 5 and 6 released NO too slowly for practical measurement by headspace analysis.

EXAMPLE 18

15 This example describes the measurement of the time course of NO production by amidine and enamine nitric oxide adducts.

To demonstrate the utility of these compounds as long-term nitric oxide releasing agents, selected 20 compounds were dissolved in phosphate buffer at pH 7.4 and incubated in a 37 °C thermostated water bath. The NO release rate was measured periodically by flushing the

solution with inert N₂ gas and then sweeping newly generated NO into a chemiluminescence detector and integrating the signal produced over the next 4-7 mins. NO release was measured over a period of two weeks.

5 None of these compounds released nitric oxide via a single pathway which produced a release profile consistent with first order kinetics. Accordingly, the results of each test are summarized here by giving the initial NO release rate, the rate at one intermediate
10 timepoint and the total time of observed NO release for representative examples.

Thus, the compound of Example V (tetrahydrozoline diazeniumdiolate) showed an initial NO release rate of 3.64 x 10⁻¹¹ moles NO per minute per milligram of
15 dissolved sample which decreased to 2.06 x 10⁻¹¹ moles NO per min. per mg. after 7 days and continued for several weeks although the last quantitative measurement showed an NO release rate of 9.00 x 10⁻¹² moles NO per min. per mg. 15 days after the beginning of the experiment.

20 Likewise, the compound of Example VI (idazoxan diazeniumdiolate) showed an initial NO release rate of 5.25 x 10⁻¹¹ moles NO/min./mg. which gradually increased to 1.41 x 10⁻¹⁰ moles NO/min./mg. after 4 days and then gradually decreased, reaching zero (i.e., no more NO was
25 being given off) by day 16.

Among the enamine-derived compounds, the compound of Example VII (the diazeniumdiolate of the morpholine enamine of cyclohexanone) showed an initial NO release rate of 4.2 x 10⁻¹¹ mole NO/min./mg. which decreased with
30 nearly first order kinetics to 1.8 x 10⁻¹¹ mole NO/min./mg. after 3 days and reached zero by day 7.


The enamine-derived diazeniumdiolate of Example VIII (from the morpholine enamine of isobutyraldehyde) showed an initial NO release rate of 3.7 x 10⁻¹¹ mole NO/min./mg.
35 which rapidly decreased to a rate of 7.0 x 10⁻¹² mole NO/min./mg. and then remained at about this level for 4 days before slowly declining, reaching zero after 7 days.

All publications cited herein are hereby incorporated by reference to the same extent as if each publication were individually and specifically indicated to be incorporated by reference and were set forth in its 5 entirety herein.

While this invention has been described with emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that the preferred embodiments may be varied. It is intended that the 10 invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the appended claims.

WHAT IS CLAIMED IS:

1. A nitric oxide-releasing amidine- or enamine-derived diazeniumdiolate having the chemical structural
5 linkage as follows:



10 wherein

$\text{C}^2 \sim \text{C}^3$ means either C^2-C^3 or $\text{C}^2=\text{C}^3$

m is 1 or 2

q is 0 or 1

15 p is 0 or 1

provided that

(1) C^2 is tetravalent, and bound to two or more of
20 C^1 , C^3 , N^1 and N^2 ;


(2) when $p=1$, then $q=0$ and $\text{C}^2 \sim \text{C}^3$ means C^2-C^3 ; or

(3) when $p=0$, and $q=1$, then $\text{C}^2 \sim \text{C}^3$ means either (i)
 $\text{C}^2=\text{C}^3$ or (ii) C^2-C^3 where C^2-N^1 means $\text{C}^2=\text{N}^1$;


(4) when $\text{C}^2 \sim \text{C}^3$ means C^2-C^3 and $q=1$ and $p=0$

25

C^2-N^1 and C^2-N^2 means




2. A compound selected from the group consisting
of




FORMULA I.

5



FORMULA II, and



FORMULA III,

10 wherein


R^1-R^3 are independently hydrogen, an unsubstituted or substituted C_{1-12} straight chain alkyl, an unsubstituted or substituted C_{3-12} branched chain alkyl, an unsubstituted or substituted C_{3-12} straight chain olefinic, an unsubstituted or substituted C_{3-12} branched chain olefinic, a substituted or unsubstituted C_{3-8} cycloalkyl, a C_{3-8} heterocyclic ring bound through a carbon atom and in which the heteroatom is oxygen or nitrogen, a substituted or unsubstituted naphthyl, a substituted or unsubstituted
15 tetrahydronaphthyl, a substituted or unsubstituted octahydronaphthyl, benzyl or substituted benzyl, substituted with up to three substituents, or phenyl or substituted phenyl, substituted with up to three substituents,
20
25 R^4 and R^5 are independently chosen from hydrogen, an unsubstituted or substituted C_{1-12} straight chain alkyl, an unsubstituted or substituted C_{3-12} branched chain alkyl, an unsubstituted or substituted C_{3-12} straight chain olefinic, an unsubstituted or substituted C_{3-12} branched chain

olefinic, a substituted or unsubstituted benzyl, an unsubstituted or substituted phenyl, a substituted or unsubstituted piperazino, a substituted or unsubstituted morpholino, amino, an unsubstituted or substituted
5 alkylamino, an unsubstituted or substituted arylamino, an unsubstituted or substituted dialkylamino, an unsubstituted or substituted diarylamino, carboxyalkylamino, carboxydialkylamino, unsubstituted or substituted tolyl, xylyl, anisyl, mesityl, an
10 unsubstituted or substituted acetyl, an unsubstituted or substituted acetoxy, carboxy, an unsubstituted or substituted carboxymethyl, an unsubstituted or substituted carboxyethyl, an unsubstituted or substituted alkylcarbonyl, thiol, an unsubstituted or substituted
15 alkylthio, an unsubstituted or substituted alkoxy, carboxamido, an unsubstituted or substituted alkylcarboxamido, or an unsubstituted or substituted dialkylcarboxamido, an unsubstituted or substituted phenoxy, an unsubstituted or substituted benzyloxy,
20 phenylcarbonyl, benzylcarbonyl, an unsubstituted or substituted nitrophenyl, trialkylsilyl or nitro,
R¹ and R² together with the nitrogen atoms to which they are bonded form a substituted or unsubstituted C₂₋₈ heterocyclic ring, or
25 R² and R³ together with the nitrogen atoms to which they are bonded form a substituted or unsubstituted C₃₋₈ heterocyclic ring, or
R¹ and R⁴ together with the nitrogen atom to which R¹ is bonded and with the carbon atom to which R⁴ is bonded
30 and with the intervening carbon atom form a substituted or unsubstituted C₂₋₆ heterocyclic ring, or
R⁴ and R⁵ together with the carbon atom to which they are bonded form an unsubstituted or substituted C₃₋₈ cycloalkyl, or a C₄₋₈ heterocyclic group in which the
35 heteroatom is selected from the group consisting of oxygen, nitrogen and sulfur, or

R⁴ and R⁵ together with the carbon atom to which they are bonded form an unsubstituted or substituted 1,4-benzodioxane, 1,3-benzodioxole, tetrahydronaphthlene, octahydronaphthalene, piperazine, morpholine, 5 tetrahydroquinoline, tetrahydroquinoxaline, tetrahydroisoquinoline.

3. A compound of claim 2 of

10



FORMULA I,

wherein

R¹-R³ are independently hydrogen, an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or unsubstituted C₃₋₈ cycloalkyl, a C₃₋₈ heterocyclic ring bound through a carbon atom and in which the heteroatom is oxygen or nitrogen, a substituted or unsubstituted 15 naphthyl, a substituted or unsubstituted tetrahydronaphthyl, a substituted or unsubstituted octahydronaphthyl, benzyl or substituted benzyl, substituted with up to three substituents, or phenyl or substituted phenyl, substituted with up to three 20 substituents,


R⁴ and R⁵ are independently chosen from hydrogen, an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, 30 an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or unsubstituted benzyl, an unsubstituted or substituted phenyl, a substituted or unsubstituted piperazino, a substituted or unsubstituted morpholino, amino, an unsubstituted or substituted

alkylamino, an unsubstituted or substituted arylamino, an unsubstituted or substituted dialkylamino, an unsubstituted or substituted diarylamino, carboxyalkylamino, carboxydialkylamino, unsubstituted or 5 substituted tolyl, xylyl, anisyl, mesityl, an unsubstituted or substituted acetyl, an unsubstituted or substituted acetoxy, carboxy, an unsubstituted or substituted carboxymethyl, an unsubstituted or substituted carboxyethyl, an unsubstituted or substituted alkylcarbonyl, thiol, an unsubstituted or substituted alkylthio, an unsubstituted or substituted alkoxy, carboxamido, an unsubstituted or substituted alkylcarboxamido, or an unsubstituted or substituted dialkylcarboxamido, an unsubstituted or substituted 10 phenoxy, an unsubstituted or substituted benzyloxy, phenylcarbonyl, benzylcarbonyl, an unsubstituted or substituted nitrophenyl, trialkylsilyl or nitro, R¹ and R² together with the nitrogen atoms to which they are bonded form a substituted or unsubstituted C₂₋₈ 15 heterocyclic ring, or R² and R³ together with the nitrogen atoms to which they are bonded form a substituted or unsubstituted C₃₋₈ heterocyclic ring, a substituted or unsubstituted C₃₋₈ heterocyclic ring, or 20 R¹ and R⁴ together with the nitrogen atom to which R¹ is bonded and with the carbon atom to which R⁴ is bonded and with the intervening carbon atom form a substituted or unsubstituted C₂₋₆ heterocyclic ring, or wherein R⁴ and R⁵ together with the carbon atom to which they are bonded 25 form an unsubstituted or substituted C₃₋₈ cycloalkyl, or a C₄₋₈ heterocyclic group in which the heteroatom is selected from the group consisting of oxygen, nitrogen and sulfur, or 30 R⁴ and R⁵ together with the carbon atom to which they are bonded form an unsubstituted or substituted 1,4-benzodioxane, 1,3-benzodioxole, tetrahydronaphthlene, octahydronaphthalene, piperazine, morpholine,

tetrahydroquinoline, tetrahydroquinoxaline,
tetrahydroisoquinoline.

4. A compound of claim 2 of

5



FORMULA II

wherein

R¹-R³ are independently hydrogen, an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or unsubstituted C₃₋₈ cycloalkyl, a substituted or unsubstituted C₃₋₈ heterocyclic ring bound through a carbon atom and in which the heteroatom is oxygen or nitrogen, a substituted or unsubstituted naphthyl, a substituted or unsubstituted tetrahydronaphthyl, a substituted or unsubstituted octahydronaphthyl, benzyl or substituted benzyl, substituted with up to three substituents, or phenyl or substituted phenyl, substituted with up to three substituents,

R⁴ is hydrogen, an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or unsubstituted benzyl, an unsubstituted or substituted phenyl, a substituted or unsubstituted piperazino, a substituted or unsubstituted morpholino, amino, an unsubstituted or substituted alkylamino, an unsubstituted or substituted arylamino, an unsubstituted or substituted dialkylamino, an unsubstituted or substituted diarylamino, carboxyalkylamino, carboxydialkylamino, unsubstituted or substituted tolyl, xylyl, anisyl, mesityl, an unsubstituted or substituted acetyl, an


unsubstituted or substituted acetoxy, carboxy, an
unsubstituted or substituted carboxymethyl, an
unsubstituted or substituted carboxyethyl, an
unsubstituted or substituted alkylcarbonyl, thiol, an
5 unsubstituted or substituted alkylthio, an unsubstituted
or substituted alkoxy, carboxamido, an unsubstituted or
substituted alkylcarboxamido, or an unsubstituted or
substituted dialkylcarboxamido, an unsubstituted or
substituted phenoxy, an unsubstituted or substituted
10 benzyloxy, phenylcarbonyl, benzylcarbonyl, an
unsubstituted or substituted nitrophenyl, trialkylsilyl
or nitro,

R¹ and R² together with the nitrogen atoms to which
they are bonded form a substituted or unsubstituted C₃₋₈
15 heterocyclic ring, or

R² and R³ together with the nitrogen atoms to which
they are bonded form a substituted or unsubstituted C₃₋₈
heterocyclic ring, or

R¹ and R⁴ together with the nitrogen atom to which R¹
20 is bonded and with the carbon atom to which R⁴ is bonded
and with the intervening carbon atom form a substituted
or unsubstituted C₂₋₆ heterocyclic ring.

5. A compound of



FORMULA III

wherein

- 5 R¹-R³ are independently hydrogen, an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted
 10 or unsubstituted C₃₋₈ cycloalkyl, a C₃₋₈ heterocyclic ring bound through a carbon atom and in which the heteroatom is oxygen or nitrogen, a substituted or unsubstituted naphthyl, a substituted or unsubstituted tetrahydronaphthyl, a substituted or unsubstituted
 15 octahydronaphthyl, benzyl or substituted benzyl, substituted with up to three substituents, or phenyl or substituted phenyl, substituted with up to three substituents,
- 20 R¹ and R² together with the nitrogen atoms to which they are bonded form a substituted or unsubstituted C₂₋₈ heterocyclic ring, or
- 25 R² and R³ together with the nitrogen atoms to which they are bonded form a substituted or unsubstituted C₃₋₈ heterocyclic ring.

6. A compound of Formula I or Formula II or Formula III of claim 2 wherein the substituents on the substituted groups is an alkoxy, acyloxy, hydroxy, halo, benzyl, acetyl, carboxyl, carboxyalkyl,
 30 carboxyalkylamido, carboxy dialkylamido, alkylcarbonyl, arylamino, diarylamino, cyano, tolyl, xylyl, mesityl, anisyl, carboxamido, amino, alkylamino, dialkylamino, formyl, dioxane, thiol, alkylthiol, aryl, heteroaryl, or phenoxy, benzyloxy, phenylcarbonyl, benzylcarbonyl,

nitrophenyl, trialkylsilyl, nitro, sulfonyl, nitrobenzyl, trialkylammonium, alkyl, cycloalkyl, tetrahydrofuranyl, tetrahydropyranyl, piperidine or morpholine.

5 7. A compound of claim 3 wherein the substituents on the substituted groups is an alkoxy, acyloxy, hydroxy, halo, benzyl, acetyl, carboxyl, carboxyalkyl, carboxyalkylamido, carboxydialkylamido, alkylcarbonyl, arylamino, diarylamino, cyano, toyl, xylyl, mesityl, 10 anisyl, carboxamido, amino, alkylamino, dialkylamino, formyl, dioxane, thiol, alkylthiol, aryl, heteroaryl, or phenoxy, benzyloxy, phenylcarbonyl, benzylcarbonyl, nitrophenyl, trialkylsilyl, nitro, sulfonyl, nitrobenzyl, trialkylammonium, alkyl, cycloalkyl, tetrahydrofuranyl, 15 tetrahydropyranyl, piperidine or morpholine.

8. A compound of claim 4 wherein the substituents on the substituted groups is an alkoxy, acyloxy, hydroxy, halo, benzyl, acetyl, carboxyl, carboxyalkyl, carboxyalkylamido, carboxydialkylamido, alkylcarbonyl, arylamino, diarylamino, cyano, toyl, xylyl, mesityl, 20 anisyl, carboxamido, amino, alkylamino, dialkylamino, formyl, dioxane, thiol, alkylthiol, aryl, heteroaryl, or phenoxy, benzyloxy, phenylcarbonyl, benzylcarbonyl, nitrophenyl, trialkylsilyl, nitro, sulfonyl, nitrobenzyl, 25 trialkylammonium, alkyl, cycloalkyl, tetrahydrofuranyl, tetrahydropyranyl, piperidine or morpholine.

9. A compound of claim 5 wherein the substituents 30 on the substituted groups is an alkoxy, acyloxy, hydroxy, halo, benzyl, acetyl, carboxyl, carboxyalkyl, carboxyalkylamido, carboxydialkylamido, alkylcarbonyl, arylamino, diarylamino, cyano, toyl, xylyl, mesityl, anisyl, carboxamido, amino, alkylamino, dialkylamino, 35 formyl, dioxane, thiol, alkylthiol, aryl, heteroaryl, or phenoxy, benzyloxy, phenylcarbonyl, benzylcarbonyl, nitrophenyl, trialkylsilyl, nitro, sulfonyl, nitrobenzyl,

trialkylammonium, alkyl, cycloalkyl, tetrahydrofuryl, tetrahydropyranyl, piperidine or morpholine.

10. A compound of Formula I or Formula II or
5 Formula III of claim 2 wherein the substituent is a
heteroaryl selected from the group consisting of pyrrole,
furan, thiophene, thiazole, pyrazole, pyran, pyridine, or
pyrimidine.

10 11. A compound of claim 7 wherein the substituent
is a heteroaryl selected from the group consisting of
pyrrole, furan, thiophene, thiazole, pyrazole, pyran,
pyridine, or pyrimidine.

15 12. A compound of claim 8 wherein the substituent
is a heteroaryl selected from the group consisting of
pyrrole, furan, thiophene, thiazole, pyrazole, pyran,
pyridine, or pyrimidine.

20 13. A compound of claim 9 wherein the substituent
is a heteroaryl selected from the group consisting of
pyrrole, furan, thiophene, thiazole, pyrazole, pyran,
pyridine, or pyrimidine.

25 14. A compound of Formula I or Formula II or
Formula III of claim 2, wherein the substituents on the
substituted groups is benzyl, tolyl, carboxyl,
carboxyalkyl, dialkylamino, arylamino or diarylamino.

30 15. A compound of Formula I of claim 3, wherein the
substituents on the substituted groups is benzyl, tolyl,
carboxyl, carboxyalkyl, dialkylamino, arylamino or
diarylamino.

35 16. A compound of Formula II of claim 4, wherein
the substituents on the substituted groups is benzyl,


tolyl, carboxyl, carboxyalkyl, dialkylamino, arylamino or diarylamino.

17. A compound of Formula III of claim 5, wherein
5 the substituents on the substituted groups is benzyl,
tolyl, carboxyl, carboxyalkyl, dialkylamino, arylamino or
diarylamino.

18. The compound of claim 5, wherein R¹ and R² are
10 hydrogen and R³ is the entire substituent attached to an
amine of a compound selected from the group consisting of
an amino acid, tryptamine, serotonin, histamine,
valcyclovir, adenosine, thyroxine, guanine, guanosine,
ubenimex, glucosamine, mannosamine, mycosamine,
15 sphingosine, thienamycin, penicillamine and rimantadine.


19. The compound of claim 5, wherein said amino
acid is selected from the group consisting of lysine,
tryptophan and hydroxy-tryptophan.
20

20. A compound selected from the group consisting
of



FORMULA IV and

25



FORMULA V

wherein R¹, R², R⁵ and R⁶ are independently hydrogen, an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic,

5 an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or unsubstituted benzyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted piperazino, a substituted or unsubstituted morpholino, amino, an unsubstituted or substituted

10 alkylamino, an unsubstituted or substituted arylamino, an unsubstituted or substituted dialkylamino, an unsubstituted or substituted diarylamino, carboxyalkylamino, carboxydialkylamino, cyano, a substituted or unsubstituted tolyl, xylyl, anisyl,

15 mesityl, an unsubstituted or substituted acetyl, an unsubstituted or substituted acetoxy, carboxy, an unsubstituted or substituted carboxymethyl, an unsubstituted or substituted carboxyethyl, an unsubstituted or substituted alkylcarbonyl, thiol, an

20 unsubstituted or substituted alkylthio, an unsubstituted or substituted alkoxy, carboxamido, an unsubstituted or substituted alkylcarboxamido, or an unsubstituted or substituted dialkylcarboxamido, a substituted or unsubstituted phenoxy, a substituted or unsubstituted


25 benzyloxy, phenylcarbonyl, benzylcarbonyl, a substituted or unsubstituted nitrophenyl, trialkylsilyl or nitro, R¹ and R² together with the carbon to which they are bonded can form a substituted or unsubstituted C^{4-C⁸} cycloalkyl,

30 R² and R³ together with the nitrogen atom to which they are bonded form a substituted or unsubstituted C₃₋₈ cycloalkyl,

R³ and R⁴ are an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or

- unsubstituted C₃₋₈ cycloalkyl, a substituted or
unsubstituted C₃₋₈ heterocyclic ring bound through a
carbon atom and in which the heteroatom is oxygen or
nitrogen, a substituted or unsubstituted naphthyl, a
5 substituted or unsubstituted tetrahydronaphthyl, a
substituted or unsubstituted octahydronaphthyl, benzyl or
substituted benzyl, substituted with up to three
substituents, or phenyl or substituted phenyl,
substituted with up to three substituents, or
- 10 R³ and R⁴ together with the nitrogen atom to which
they are bonded can form a C₃₋₈ heterocyclic ring or a C₃₋₈
substituted heterocyclic ring or a C₃₋₈ unsubstituted or
substituted heterocyclic ring containing up to two
additional heteroatoms selected from the group O, S, N,
15 or
- R¹ and R⁶ together with the C=C-C through which they are
bonded form an unsubstituted or substituted
cycloalkyl, or
- 20 R⁵ and R⁶ together with the carbon to which they are
bonded can form a substituted or unsubstituted C₄₋₈
cycloalkyl.

21. A compound of




FORMULA IV

- 5 wherein R¹ and R² are independently hydrogen, an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted C₃₋₁₂ branched chain
- 10 olefinic, a substituted or unsubstituted benzyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted piperazino, a substituted or unsubstituted morpholino, amino, an unsubstituted or substituted alkylamino, an unsubstituted or substituted arylamino, an
- 15 unsubstituted or substituted dialkylamino, an unsubstituted or substituted diarylamino, carboxyalkylamino, carboxydialkylamino, cyano, a substituted or unsubstituted toyl, xylyl, anisyl, mesityl, an unsubstituted or substituted acetyl, an
- 20 unsubstituted or substituted acetoxy, carboxy, an unsubstituted or substituted carboxymethyl, an unsubstituted or substituted carboxyethyl, an unsubstituted or substituted alkylcarbonyl, thiol, an unsubstituted or substituted alkylthio, an unsubstituted
- 25 or substituted alkoxy, carboxamido, an unsubstituted or substituted alkylcarboxamido, or an unsubstituted or substituted dialkylcarboxamido, a substituted or unsubstituted phenoxy, a substituted or unsubstituted benzyloxy, phenylcarbonyl, benzylcarbonyl, a substituted or unsubstituted nitrophenyl, trialkylsilyl or nitro,
- R³ and R⁴ are an unsubstituted or substituted C₁₋₁₂ straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted

C_{3-12} branched chain olefinic, a substituted or unsubstituted C_{3-8} cycloalkyl, a substituted or unsubstituted C_{3-8} heterocyclic ring bound through a carbon atom and in which the heteroatom is oxygen or 5 nitrogen, a substituted or unsubstituted naphthyl, a substituted or unsubstituted tetrahydronaphthyl, a substituted or unsubstituted octahydronaphthyl, benzyl or substituted benzyl, substituted with up to three substituents, or phenyl or substituted phenyl, 10 substituted with up to three substituents.

22. A compound of



FORMULA V

15

wherein R^5 and R^6 are independently hydrogen, an unsubstituted or substituted C_{1-12} straight chain alkyl, an unsubstituted or substituted C_{3-12} branched chain alkyl, an unsubstituted or substituted C_{3-12} straight chain olefinic, 20 an unsubstituted or substituted C_{3-12} branched chain olefinic, a substituted or unsubstituted benzyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted piperazino, a substituted or unsubstituted morpholino, amino, an unsubstituted or substituted alkylamino, an unsubstituted or substituted arylamino, an 25 unsubstituted or substituted dialkylamino, an unsubstituted or substituted diarylamino, carboxyalkylamino, carboxydialkylamino, cyano, a substituted or unsubstituted tolyl, xylyl, anisyl, mesityl, an unsubstituted or substituted acetyl, an 30 unsubstituted or substituted acetoxy, carboxy, an unsubstituted or substituted carboxymethyl, an unsubstituted or substituted carboxyethyl, an

- unsubstituted or substituted alkylcarbonyl, thiol, an unsubstituted or substituted alkylthio, an unsubstituted or substituted alkoxy, carboxamido, an unsubstituted or substituted alkylcarboxamido, or an unsubstituted or
5 substituted dialkylcarboxamido, a substituted or unsubstituted phenoxy, a substituted or unsubstituted benzyloxy, phenylcarbonyl, benzylcarbonyl, a substituted or unsubstituted nitrophenyl, trialkylsilyl or nitro,
R³ and R⁴ are an unsubstituted or substituted C₁₋₁₂
10 straight chain alkyl, an unsubstituted or substituted C₃₋₁₂ branched chain alkyl, an unsubstituted or substituted C₃₋₁₂ straight chain olefinic, an unsubstituted or substituted C₃₋₁₂ branched chain olefinic, a substituted or unsubstituted C₃₋₈ cycloalkyl, a substituted or
15 unsubstituted C₃₋₈ heterocyclic ring bound through a carbon atom and in which the heteroatom is oxygen or nitrogen, a substituted or unsubstituted naphthyl, a substituted or unsubstituted tetrahydronaphthyl, a substituted or unsubstituted octahydronaphthyl, benzyl or
20 substituted benzyl, substituted with up to three substituents, or phenyl or substituted phenyl, substituted with up to three substituents.

23. The compound in claim 22 wherein, in Formula V,
25 R² and R³, together with the carbon and nitrogen atom to which they are bonded, form a C₃₋₈ cycloalkyl.

24. The compound of claim 23 wherein the C₃₋₈ cycloalkyl is substituted with a heteroatom.
30

25. The compound of claim 22 wherein R⁵ and R⁶, together with the C=C-C through which they are bonded form a C₃₋₁₂ alicyclic hydrocarbon.

35 26. The compound of claim 21 wherein, R³ and R⁴, together with the nitrogen to which they are bonded form a C₃₋₈ cycloalkyl.

27. The compound of claim 26 wherein the C₃₋₈ cycloalkyl is further substituted with a heteroatom, or an aromatic ring, which can be substituted with a C₁₋₆ alkyl or a C₁₋₆ alkoxy, and R¹ and R² can form a C₃₋₈ cycloalkyl.

28. A method of treating an animal with a biological disorder treatable with nitric oxide, which 10 method comprises administering to the animal an amount from an enamine- or an animine-derived diazeniumdiolate sufficient to treat the biological disorder in the animal.


15 29. A method of producing a nitric oxide-releasing amidine- or enamine-derived diazeniumdiolate from a compound containing an amine, wherein said amine is a primary amine or a secondary amine, which method comprises:

20 (a) treating amine with an acetamidating agent so as to form an acetamidine derivative of the amine-containing compound, and,

(b) treating the acetamidine derivative with nitric oxide gas to form an amidine-derived diazeniumdiolate.

25

30. A compound produced in accordance with the method of claim 29.





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|--|---|
| (51) International Patent Classification ⁶ : C07D 291/08, 295/12, 233/96, A61K 31/655 | | A3 | (11) International Publication Number: WO 99/01427 (43) International Publication Date: 14 January 1999 (14.01.99) |
| <p>(21) International Application Number: PCT/US98/13723</p> <p>(22) International Filing Date: 1 July 1998 (01.07.98)</p> <p>(30) Priority Data: 60/051,690 3 July 1997 (03.07.97) US</p> <p>(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health Office of Technology Transfer [US/US]; Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): HRABIE, Joseph, A. [US/US]; 630 Grant Place, Frederick, MD 21702-4144 (US). KEEFER, Larry, K. [US/US]; 7016 River Road, Bethesda, MD 29817 (US).</p> <p>(74) Agents: GAGALA, Bruce, M. et al.; Leydig, Voit & Mayer, Ltd., Two Prudential Plaza, Suite 4900, 180 North Stetson, Chicago, IL 60601-6780 (US).</p> | | <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p> <p>(88) Date of publication of the international search report: 25 March 1999 (25.03.99)</p> | |
| <p>(54) Title: NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME</p> <p>(57) Abstract</p> <p>The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions comprising such compounds, methods of using such compounds and compositions, and to a method for the preparation of nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

INTERNATIONAL SEARCH REPORT

Inter Application No
PCT/EP98/13723

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D291/08 C07D295/12 C07D233/96 A61K31/655

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|------------------------------|
| A | WO 96 40665 A (THE UNITED STATES OF AMERICA) 19 December 1996 see page 1; claim 1 --- | 1, 2, 5, 20-22, 28, 30 |
| A | US 5 155 137 A (L. K. KEEFER ET AL) 13 October 1992 cited in the application see claims 1,12 --- -/- | 1, 2, 5, 20-22, 28, 30 |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

15 December 1998

14/01/1999

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Voyiazoglou, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/13723

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|---------------------------|
| A | CHEMICAL ABSTRACTS, vol. 85, no. 21, 1976 Columbus, Ohio, US; abstract no. 159592W, L.B. VOLODARSKII ET AL : "Preparation and properties of N-nitroso-alpha-hydroxylamino oximes" page 505; XP002087968 see abstract & IZV. SIB. OTD. AKAD. NAUK. SSSR, SER. KHIM. NAUK , no. 4, 1976, pages 136-140, --- | 1,2,5, 20-22,30 |
| A | US 5 212 204 A (L. K. KEEFER ET AL) 18 May 1993 see claim 10 --- | 1,2,5, 20-22, 28,30 |
| A | J. P. FREEMAN ET AL : "Alkaline decomposition of nitrosohydroxylamine derivatives" JOURNAL OF ORGANIC CHEMISTRY, vol. 35, no. 9, 1970, pages 3107-3110, XP002087967 EASTON US see page 3110, left-hand column, line 43 - line 52 --- | 1,2,5, 20-22,30 |
| A | DATABASE WPI Week 8508 Derwent Publications Ltd., London, GB; AN 85-047728 XP002087969 "New N,N'-dihydroxydiazenum propanol derivs. - for prevention and treatment of apple canker" & JP 60 006651 A (OJI CORN SRARCH & UNIV. OF TOKYO), 14 January 1985 see abstract --- | 1,2,5, 20-22,30 |
| A | WO 93 13055 A (THE WELLCOME FOUNDATION) 8 July 1993 see claims 1,10 --- | 1,2,5, 20-22, 28,30 |
| A | WO 94 27957 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 8 December 1994 see page 17; claim 1 ---- | 1,2,5, 20-22, 28,30 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/13723

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 28 because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 28 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking(Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 98/13723

| Patent document cited in search report | Publication date | Patent family member(s) | | | Publication date |
|--|------------------|--|---|--|--|
| WO 9640665 | A 19-12-1996 | US AU CA EP | 5721365 A 6271496 A 2223426 A 0836597 A | | 24-02-1998 30-12-1996 19-12-1996 22-04-1998 |
| US 5155137 | A 13-10-1992 | AT AU AU CA DE DE EP ES JP JP WO US US | 140446 T 649739 B 8712391 A 2091994 A 69120955 D 69120955 T 0549704 A 2093108 T 2537445 B 6501686 T 9205149 A 5683668 A 5250550 A | | 15-08-1996 02-06-1994 15-04-1992 21-03-1992 22-08-1996 21-11-1996 07-07-1993 16-12-1996 25-09-1996 24-02-1994 02-04-1992 04-11-1997 05-10-1993 |
| US 5212204 | A 18-05-1993 | AT AU AU CA DE DE EP ES JP WO | 133861 T 637845 B 6621190 A 2070388 A,C 69025336 D 69025336 T 0501975 A 2084041 T 5504760 T 9105551 A | | 15-02-1996 10-06-1993 16-05-1991 19-04-1991 21-03-1996 05-09-1996 09-09-1992 01-05-1996 22-07-1993 02-05-1991 |
| WO 9313055 | A 08-07-1993 | AU AU EP HU IL JP NZ ZA | 669345 B 3169293 A 0618898 A 70502 A 104212 A 7502512 T 246202 A 9210018 A | | 06-06-1996 28-07-1993 12-10-1994 30-10-1995 22-02-1998 16-03-1995 28-05-1996 23-06-1994 |
| WO 9427957 | A 08-12-1994 | US AU EP JP | 5374710 A 7045194 A 0700378 A 8511252 T | | 20-12-1994 20-12-1994 13-03-1996 26-11-1996 |